

ASX Announcement

Medibio Limited – 18 June 2018



Medibio to provide Corporate Health Investor Presentation

Sydney, Australia and Minneapolis, MN USA – 18 June 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, announced today that Senior Vice President of Corporate Health, Peta Slocombe, will present in front of up to 200 investors at the forthcoming Finance News Network investor conference in Sydney on Tuesday, 19 June between 12:30pm and 2:30pm.

The opportunity includes a pre-recorded interview for public viewing, providing highlights and an overview of the Company's recently launch Corporate Health product and platform, and will be available on the corporate websites of Shaw and Partners, ANZ, St. George Bank, Westpac, Thomas Reuters, and Sequoia Finance Group.

Attendees are invited to [register](#) to secure seating at the event at no cost via the Finance News Network website. The associated presentation is attached and available on the Company's website alongside a post event release of the interview conducted on the day.

- ENDS -

ASX Announcement



Medibio Limited – 18 June 2018

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:

Website: www.medibio.com.au

Shareholder and Investor Inquiries:

Stephanie Ottens
Investor Relations Director
Medibio Limited
stephanie.ottens@medibio.com.au
T: +61 434 405 400

Media Inquiries:

Josh Purdy
Senior Public Relations Manager
Medibio Limited
josh.purdy@medibio.com.au
T: +1 952-222-0551 ext. 208
M: +1 612-695-0168

medibio

Finance News Network Presentation

June 2018

© 2018 Medibio Limited



FORWARD LOOKING STATEMENTS

The purpose of the presentation is to provide an update of the business of Medibio Limited **(ASX:MEB) (OTCQB: MDBIF)**. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfillment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

The logo for medibio, featuring the word in a lowercase, sans-serif font. The letters 'me' are dark blue, 'di' are purple, and 'bio' are orange. The background consists of a pattern of white dots of varying sizes, arranged in a grid that tapers towards the center, creating a subtle sunburst or starburst effect.

medibio

The mental health technology and services company using objective physiologic data to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions.


The Challenge



THE CHALLENGE BY NUMBERS

In Organizations

Mental Health in the Workplace



In Society

Stigma and lack of access are prevalent globally

21 million suicide attempts from mental illness

Of those, nearly **1 million** are successful



300 MILLION suffer from depression

1 in 13 suffer from anxiety

7.7 MILLION PTSD sufferers in the United States alone

In the Health Care System

Only **1 psychiatrist per 100,000 people** in over half the countries in the world

40% of countries have less than one hospital bed reserved for mental disorders **per 10,000 people**

Out of **350 million** patients globally **< 7%** receive optimal treatment

50% are never diagnosed

30% are incorrectly diagnosed

\$94.5 BILLION direct cost to treat Major Depressive Disorder (MDD) annually in the USA

\$12.6 BILLION direct cost to treat depression annually in Australia

The Solution



THREE UNIQUE VERTICALS ADDRESS THE CHALLENGE

20 Million Covered Lives By 2020

Vertical 1: CORPORATE HEALTH

Personalised solutions in employee and organizational mental health.

Launched May 2018

**~64 million
lives¹**

Vertical 2: CONSUMER HEALTH

Empowering consumers to track and manage mental health.

Launching Q1 FY19

**~266 million
lives²**

Vertical 3: INTEGRATED HEALTH

Clinical decision support systems, enabling clinicians to monitor and manage their patient populations.

Launching Q3 FY19

**~450 million
lives³**

1. Based on employment in USA and Australia
2. Based on adult population in USA and Australia
3. Based on people in the world currently suffering from a mental health condition

MEDIBIO CORPORATE HEALTH & INSURANCE PRODUCT LINE

Medibio Inform
CORPORATE HEALTH



Entry Level

A mental health assessment + biometric snapshot into your organizations' mental health.

\$5 per capita/per person for a 4 week program

Illuminate + IlluminateExecutive
CORPORATE HEALTH



Subscription Based

End to end mental health program from proactive, high performance and executive, to telepsych support and triage.

**\$68 per capita per annum
\$1500 per executive per annum**

Incentify
INSURANCE



White Labelled

Real time monitoring & management for policyholders. Prospective and retrospective data analytics from your population.

Custom pricing

The world's most advanced combined psychological and biometric technology platform.

medibio

CONSUMER OFFERING

TRANSFORMING MENTAL HEALTH OUTCOMES

Empowering individuals to monitor mental health and wellbeing like never before.

Insights is the mobile mental health system combining digital biomarkers from wearables and subjective monitoring, to put personalized mental health in the palm of the consumers hand.

- Wearable driven Mental Health scoring that allows the user to baseline and manage their Mental Health journey with biometric feedback
- Interactive mood tracking and journaling that enables users to proactively manage episodes of mental illness
- Integrates with all heart rate enabled devices from Garmin, Apple & Fitbit
- Compatible with most smartphones & tablets on Android & iOS
- Upgrade to Insights Pro to get deeper biometric insights, unlimited history and storage of your mental health readings, plus data sharing capabilities via the Logics professional portal with caregivers and clinicians

▶ To be available for purchase at \$9.99 per month or \$99 per year



insights
by Medibio

INTEGRATED HEALTH



Index is a regulated medical device software for Apple and Android mobile platforms to allow the collection of high-fidelity biomarkers.

iOS and Android apps empower mental health patients and their practitioners with a concentrated, highly personalized, objective understanding of mental health, complemented by management tools to ensure better quality of life.

Featuring the Index biometric reporting, the app includes the functionality Of the Insights app plus:

- Regulated data collection device and software platform
- Integration with regulated, skin worn ECG patch medical devices
- Diagnosis aide for mental health indications
- Compliance and feedback tracking
- Monitoring of mental health indications
- Depression Episodes
- Longitudinal data integration on Medibio portal
- Mental Health Care Plans




Logics Professional Portal is a cloud-based, HIPAA-compliant platform allowing providers to gather, interpret and manage near real-time mental health patient data.

The platform will provide a longitudinal view into both Insights and Index data, including information on risk stratification, early detection, monitoring and intervention, treatment response and efficacy, along with tools to program and provide proactive patient care.


Features include:

- Longitudinal view of data points - heart rate, sleep, mood tracking, medication adherence, therapy engagement
- Engagement with Insight scoring and utilization of platform features for wellness management
- High resolution Index mental health biometric data analytics



EMERGING DIVISION

DIGITAL THERAPEUTICS



Therapy
Adherence and
Effectiveness



Future
Formulation
and Tracking



CRO
Support



Technology for
clinical trials,
academic research

Current Partnerships and Projects in Process



MAYO
CLINIC



- Ketamine Titration and Effectiveness
- Differential Diagnosis



medibio

The Science



A HISTORY OF PIONEERING RESEARCH MENTAL ILLNESS AND BIOMARKERS IN THE HUMAN BODY

Physiology

Our approach exploits features of cardiovascular physiology influenced directly by the autonomic nervous system and susceptible to disruption during sleep, as a source of biometrics that correlate with onset and existence of mental dysfunction.

20 plus years*
of data collected

Data Science

Our approach focuses on using Artificial Intelligence to monitor mental illness types (such as depression, anxiety and stress) and potential physiological metrics, so we can predict irregularity and future recurrent episodes.

A comprehensive patent suite
+ CHR, technology, and diagnostics


The relationship between psychiatric illness and the circadian pattern of heart rate.
Hans G. Stampfer, Australian and New Zealand Journal of Psychiatry 1998; 32:187-198.

medibio

PHYSIOLOGICAL SCIENCE

THE CIRCADIAN CARDIAC AND SLEEP RELATIONSHIP

The autonomic nervous system (ANS) is comprised of two arms:



PARASYMPATHETIC SYSTEM

PARASYMPATHETIC SYSTEM (PS)

Plays a key role in growth, **restorative processes**, anabolic activities, conservation of bodily energy and resting of vital organs


Modulation controls physiological stability

Activity is recessive (**night-time**)

SYMPATHETIC SYSTEM (SS)

Prepares us for the fight or flight situations, keeping the body in a constant state of alert

Activity is predominant (**day-time**)



SYMPATHETIC SYSTEM


The ANS is continuously seeking balance of these two major components

The Company



MEDIBIO BY THE NUMBERS

OUR GLOBAL PRESENCE



32
patents
and provisional
patents in our
portfolio

53
employees

25,000+ current covered lives

54%

of total
budget
invested
in R&D

23

Years of
Patient Data
Collected

200+

years of combined professional
psychological experience



2
certifications

CORPORATE STRUCTURE

CAPITAL STRUCTURE (ASX:MEB) (OTCQB: MDBIF)

Market Cap	AU\$35M
Share Price <i>as of 30 May 2018</i>	AU\$0.17
Shares on Issue	203M
Cash Available¹	AU\$13.5M

1. Cash balance of \$11.6M at March 31, 2018 plus anticipated inflows from option purchases, partly paid share, and grants
2. Percentage of shares on issue
3. Percentages based on available information, including share registry, options listing, ASX filings, and other reported data
4. Includes shares on issue and options

Significant Institutional Investors

- **FIDELITY 9.1%**
- **REGAL FUNDS MANAGEMENT 7.0%**
- **IFM INVESTORS 4.9%**

Shareholder Mix³

- **PRIVATE HOLDERS 46%**
- **INSTITUTIONAL HOLDERS 43%**
- **BOARD AND MANAGEMENT 11%⁴**

BOARD OF DIRECTORS



CHRIS INDERMAUR
Chairman



JACK COSENTINO
CEO/Managing Director



PETER CARLISLE
Managing Director, Olympics &
Action Sports, Octagon Worldwide



PATRICK KENNEDY
Former US Congressman
Founder, Kennedy Forum
Non Executive Director



DR FRANKLYN G PRENDERGAST
Former member board of Trustee
and Board of Governors
Mayo Clinic and Medibio
Non Executive Board Member



MICHAEL PHELPS
Non Executive Director




ANDREW MAXWELL
Non Executive Director



BRIAN MOWER
Chief Financial Officer

RECENT MILESTONES

TIMING NOTED IS FY



FUTURE MILESTONES

TIMING NOTED IS FY



21 million suicide attempts from mental illness. Of those, nearly 1 million are successful

End to end solutions for mental healthcare

20+ years of scientific rigor

Well structured and ready to capture the total addressable market

Corporate Health

Estimated Addressable Market: **64 million** employees (US and Australia)

Consumer Market

Estimated Addressable Market: **85 million+**

*based on ¼ of adult population in US and Australia

Integrated Health

Market Size: **66 million** US mental health visits per year

The Challenge

The Solution

The Science

The Company

The Opportunity

THANK YOU

Peta Slocombe

SVP Corporate Health

peta.slocombe@medibio.com.au